Business Context and Reporting Period
This Form 8-K was filed by Oncobiologics, Inc. (noted as Outlook Therapeutics, Inc. in metadata) on July 13, 2018, reporting events occurring on July 10, 2018. The registrant is an emerging growth company incorporated in Delaware with principal executive offices in Cranbury, New Jersey.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance status regarding Nasdaq listing requirements.
Material Changes and Listing Status
- Market Value Compliance: The Company received formal notification from Nasdaq on July 10, 2018, that it has evidenced compliance with the $35 million market value of listed securities requirement. The hearing matter regarding this requirement has been closed.
- Bid Price Non-Compliance: The Company remains subject to a 180-day grace period ending October 23, 2018, to regain compliance with the minimum $1.00 per share bid price requirement.
- Compliance Criteria: To satisfy the bid price requirement, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before October 23, 2018.
Outlook, Risks, and Contingencies
If the Company fails to regain compliance with the $1.00 bid price requirement by the October 23, 2018 deadline, its securities would be subject to delisting. However, the Company retains the right to request a hearing before a Nasdaq Hearings Panel, which would stay any delisting action pending the conclusion of the hearing process. A press release detailing these events was issued on July 11, 2018, and is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the current stock bid price to assess progress toward the $1.00 threshold.
- Monitor the Company's ability to maintain a closing bid price of at least $1.00 for ten consecutive business days before October 23, 2018.
- Review the press release filed as Exhibit 99.1 for additional management commentary.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.